November 9, 2020
Startup Savran Technologies aims to detect disease recurrence in triple negative breast cancer (TNBC) patients with its microfluidic platform, which isolates and quantifies circulating tumor cells (CTCs). The company believes the method could complement circulating tumor DNA (ctDNA)-based approaches to monitor for minimal residual disease (MRD).
Savran Technologies to Target Breast Cancer Recurrence with Circulating Tumor Cell Platform
November 9, 2020
Each cancer patient’s tumors have cells that look and act differently, making it difficult for scientists to determine treatments based on tumors grown from generic cell cultures in the lab.
November 6, 2020
Like poets and painters, scientists are often inspired by nature. In a recent example, researchers have taken inspiration both from the webs and compound eyes of spiders to create a 3D photodetection system with a large field of view and no aberration (Adv. Mater., doi: 10.1002/adma.202004456).
November 6, 2020
Fogarty grantee Dr. Young Kim has won the $400,000 first prize in the NIH Technology Accelerator Challenge.
Read More about "Fogarty mHealth grantee wins NIH tech competition"
November 4, 2020
Researchers with the Purdue Institute of Inflammation, Immunology and Infectious Disease are developing a Covid-19 diagnostic test. The test is a small sensor that will be able to produce rapid results given a sample of saliva. The sensors are being created in conjunction with IdentifySensors Biologics Corporation. The goal of the sensor is to be able to connect with smartphones and transmit fast, reliable data to reduce Covid transmission.
November 2, 2020
The Institute of Inflammation, Immunology and Infectious Disease at Purdue University has partnered with Cleveland-based technology firm IdentifySensors Biologics to develop a rapid diagnostic platform for detecting pathogens, including SARS-CoV-2, the virus that causes COVID-19.
New electronic diagnostic test sends COVID-19, other pathogen test results to smartphones
November 1, 2020
Many patients with pancreatic cancer have only about a 10% chance of survival within five years of their diagnosis because they tend to become resistant to chemotherapy, past studies have indicated.
Testing Drugs Within A Tumor May Combat Pancreatic Cancer Drug Resistance, ‘Time Machine’ Suggests
October 31, 2020
Pancreatic cancer is one of the deadliest forms of the disease in humans. One thing that makes it so dangerous is its resistance to chemotherapy. A team at Purdue University says part of the problem is research which focuses on one cancer cell type at a time. Their study introduces their solution to this problem — a cancer “time machine” which looks at the disease’s behavior over time.
Pancreatic cancer ‘time machine’ creates new way to test potential treatments
October 31, 2020
Pancreatic cancer is one of the deadliest forms of the disease in humans. One thing that makes it so dangerous is its resistance to chemotherapy. A team at Purdue University says part of the problem is research which focuses on one cancer cell type at a time. Their study introduces their solution to this problem — a cancer “time machine” which looks at the disease’s behavior over time.
October 30, 2020
Purdue Veterinary Medicine Dean Willie Reed continued a fall tradition virtually this month, giving his annual State of the College address to students using the Zoom platform. The event, held at 12:30 p.m. Monday, October 19, attracted nearly 200 participants – a virtual crowd similar in size to the audiences that customarily heard the presentation in-person in Lynn 1136 in past years. Dean Reed delivered a positive message of progress, describing ways in which the college is moving forward on multiple fronts.
Dean’s State of the College Address Describes How Purdue Veterinary Medicine is Moving Forward
